OPA868-1

OPA868-1 is a preclinical-stage therapeutic candidate developed by Serilink Biotechnology, a company specializing in advanced conjugation technologies. It is part of the company's pipeline of next-generation conjugates, which includes antibody-drug conjugates (ADCs), peptide-drug conjugates (PDCs), and antibody-radionuclide conjugates (ARCs). OPA868-1 leverages Serilink's proprietary linker-payload technology, designed to optimize the delivery of therapeutic agents to specific targets while enhancing stability and reducing off-target toxicity. The drug is primarily being investigated for the treatment of solid tumors. As of current public disclosures, the specific biological target and the nature of the payload for OPA868-1 remain undisclosed by the sponsor.